TITLE:
Problem of Invasive Cervical Cancer’s Management in the Obstetric Gynecologic Department of the National Hospital Donka, Conakry
AUTHORS:
Moussa Kantara Camara, Daniel Williams Atanase Leno, Kèlètigui Traore, Aboubacar Fodé Momo Soumah, Ousmane Balde, Yolande Hyjazi, Namory Keita
KEYWORDS:
Cervix, Invasive Cancer, Problems, Survival
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.7 No.12,
November
24,
2017
ABSTRACT: Introduction: The objectives of this study were to
describe the diagnostic and therapeutic aspects, identify problems and evaluate
the survival rate of invasive cervical cancer patients. Patients and method: It
was a retrospective descriptive study of 7 years from 1 January 2006 to 31
December 2012. Records
of invasive cervical cancer were histologically confirmed. The clinical and therapeutic data collected
were transferred to Epi info 7 and SSPS version 18 software with a significance
level p as used to provide information on the vital condition
after confidential agreement. Kaplan Meier was used to assess the overall
survival rate. Results: Invasive cancer of the cervix was frequent (58.79%)
with an annual median rate of 16.7%, with extremes of 5.8% and 20.6%. 88.70% of
the patients was referred from regions of the country (54.02%); the median age was 50 years with extremes of 16 and 84 years and a peak
of 29.6% between 35 and 44 years; 76.20% were housewives; uneducated women were about 60.12%; Stage III was about 45.3%. Most of the patients were confirmed
histologically after 30 days (68%). The means of treatment were surgery about
91 (29.26%), palliation 75 (24.12%), radiotherapy 59 (18.97%) and chemotherapy
41 (13.18%) with surgery (9, 65%) or radiotherapy (4.82%). The main
complication was metrorrhagia, 164 cases (56.55%), with overall survival rate
of 51.8% at 2 years and 5.1% at 5 years. Conclusion: Invasive cervical cancer
in later stages is treated for low survival in the context of our work. Early
detection and treatment of precancerous lesions would reduce the incidence and
mortality of this cancer.